Volume 57, Issue 4

Search all Cancer Chemotherapy and Pharmacology articles

April 2006

Filter by

Volume:

Sort by

Date published:

New to old Old to new

16 articles in this issue

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
Jane E Latz
Ajai Chaudhary
Robert D Johnson
Original Article 02 December 2005 Pages: 401 - 411
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy
Jane E Latz
Mats O Karlsson
Robert D Johnson
Original Article 02 December 2005 Pages: 412 - 426
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy
Jane E. Latz
James J. Rusthoven
Robert D. Johnson
Original Article 02 December 2005 Pages: 427 - 435
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma
Seok Jin Kim
Hee Yun Seo
Jun Suk Kim
Original Article 28 July 2005 Pages: 436 - 442
Interpreting cell cycle effects of drugs: the case of melphalan
Monica Lupi
Paolo Cappella
Paolo Ubezio
Original Article 30 September 2005 Pages: 443 - 457
A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer
Jeffrey M. Skolnik
Jeffrey S. Barrett
Peter C. Adamson
Original Article 27 September 2005 Pages: 458 - 464
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K. Ramanathan
Marwan Fakih
Merrill J. Egorin
Original Article 25 August 2005 Pages: 465 - 474
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children
P. Kellie Turner
Lisa C. Iacono
Clinton F. Stewart
Original Article 27 July 2005 Pages: 475 - 482
Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro
Jocelyn L Carr
Malcolm D Tingle
Mark J McKeage
Original Article 20 September 2005 Pages: 483 - 490
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
Maria Serova
Fabien Calvo
Eric Raymond
Original Article 02 August 2005 Pages: 491 - 499
Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles
Sulbha Sharma
Alok Dube
Pradeep K Gupta
Original Article 02 August 2005 Pages: 500 - 506
Apoptosis induced by glycoprotein (150-kDa) isolated from Solanum nigrum L. is not related to intracellular reactive oxygen species (ROS) in HCT-116 cells
Sei-Jung Lee
Kye-Taek Lim
Original Article 06 October 2005 Pages: 507 - 516
Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells
Michelutti Angela
Stocchi Raffaella
Damiani Daniela
Original Article 05 July 2005 Pages: 517 - 524
Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells
Yi-Hsien Lin
Jen-Hwey Chiu
Sang-Hue Yen
Original Article 20 September 2005 Pages: 525 - 532
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Monika Jermann
Rolf A Stahel
Miklos Pless
Original Article 29 July 2005 Pages: 533 - 539
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
Silwan Chedid
Edgardo Rivera
Massimo Cristofanilli
Original Article 29 September 2005 Pages: 540 - 544

Volume 57, Issue 4

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma

Interpreting cell cycle effects of drugs: the case of melphalan

A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells

Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles

Apoptosis induced by glycoprotein (150-kDa) isolated from Solanum nigrum L. is not related to intracellular reactive oxygen species (ROS) in HCT-116 cells

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

Navigation